A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer

Trial Profile

A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Trametinib (Primary) ; Uprosertib (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Results analysing clinical activity and safety of trametinib [GSK-1120212] + GSK2141795 in patients with recurrent or metastatic cervical cancer, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 10 Aug 2016 Status changed from suspended to discontinued due to problems related to drug supply.
    • 12 Jun 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top